Bilgehan Aygen; Neşe Demirtürk; Orhan Yıldız; Mustafa Kemal Çelen; İ̇lhami Çelik; Şener Barut; Onur Ural; Ayşe Alga Batırel; Reşit Mıstık; Funda Şimşek; Ali Aşan; Gülden Ersöz; Nesrin Türker; Hüseyin Bilgin; Sami KINIKLI; Faruk Karakeçili; Gökmen Zararsız

The role of insurance providers in supporting treatment and management of hepatitis C patients

BMC Health Services Research 19(1) (2019)

Masoud Behzadifar; Hasan Abolghasem Gorji; Aziz Rezapour; Meysam Behzadifar; Nicola Luigi Bragazzi

Impact of Severity of Chronic Liver Disease on Health Related Economics

Hepatitis Monthly 20(6) (2018)

Fakhar Ali Qazi Arisar; Muhammad Ali Kamran; Ramlah Nadeem; Wasim Jafri

Economic Burden of Inflammatory Bowel Disease in Shiraz, Iran

Archives of Iranian Medicine 26(1) (2023)

Leila Rahmati; Alireza Mooghali; Seyed Mohammad Hosein Kamani; Fatemeh Zare; Hassan Askari; Ali Reza Safarpour

Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme

International Journal of Clinical Pharmacy 43(4) (2020)

Salamat Ali; Tofeeq Ur-Rehman; Mashhood Ali; Sayeed M Haque; Faisal Rasheed; Eleri Lougher; Muhammad Sarfraz Nawaz; Vibhu Paudyal

The Estimation of Economic Burden of Hepatitis B Virus Infection in Iran

Hepatitis Monthly 17(1) (2017)

Mehdi Mohammadzadeh; Behnaz Fattahi; Tayebeh Ghari

Seronegative occult hepatitis C infection among hemodialysis patients: A prevalence study

Therapeutic Apheresis and Dialysis 25(2) (2020)

Shahab Mahmoudvand; Somayeh Shokri; Azarakhsh Azaran; Seyed Saeed Seyedian; Manoochehr Makvandi; Habibollah Mirzaei; Sheida Behzadi Sheikhrobat

The Evaluation of Interferon Lambda 4 rs368234815 as a Predictor Factor in Treated Patients with Chronic Hepatitis C Genotype 1a Infection

Indian Journal of Medical Microbiology 35(2) (2017)

Shahram Jalilian; Seyed Mahmoud Latifi; Manoochehr Makvandi; Ali Teimoori; Azarakhsh Azaran; Mehdi Parsanahad; Gholam Abbas Kaydani

MDR1 gene C3435T polymorphism in chronic hepatitis C patients

Microbial Pathogenesis 114 (2017)

Mehdi Parsanahad; Manoochehr Makvandi; Ali Teimoori; Shahram Jalilian; Gholam Abbas Kaydani; Sara Mahmoodi

Evaluating the Prevalence of HBV, HCV, and HIV in Hemodialysis Patients in North Cyprus

Hepatitis Monthly In Press(In Press) (2019)

Meryem Güvenir; Emrah Güler; Deren Oygar; Ahmet Behlül; Kaya Süer

Clinical Efficacy and Safety of Direct-Acting Antivirals in Chronic Hepatitis C Treatment: Real-World Data

Viral Hepatitis Journal 29(3) (2023)

Ayla Doğrugörün; Elif Doyuk Kartal; Saygın NAYMAN ALPAT

Cost-of-illness analysis of ulcerative colitis patients treated with biological therapy: a prospective observational study in Iran

BMC Health Services Research 25(1) (2025)

Hassan Karami; Amin Ghanbarnejad; Mitra Nowrouzpour; Ali Mouseli; Reihaneh Taheri Kondar; Maryam Shirvani Shiri; Farbod Ebadi Fard Azar

Prevalence of hepatitis E virus in thalassemia patients with hepatitis C in Tehran, Iran

Iranian Journal of Microbiology 11(6) (2020)

Najmeh Dalvand; Azadeh Dalvand; Zohreh Sharifi; Seyed Masoud Hosseini

Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia

Hepatitis Monthly 18(1) (2018)

Ligita Jančorienė; Katažyna Polubenko; Edita Kazėnaitė; Arida Buivydienė; Jolita Jakutiene; Ieva Tolmane; Agita Jēruma; Daiva Radzišauskienė; Evelina Mockienė; Arvydas Ambrozaitis

Socio-economic assessments of Hepatitis C Virus infection: Evidence from Vehari district of Pakistan

Archives of Hepatitis Research (2021)

Ahmed Dilshad; Shakeel Muhammad; Tariq Bilal; Mahmood Tariq

Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules

Hepatitis Monthly In Press(In Press) (2019)

Figen Sarıgül Yıldırım; Murat Sayan; Ülkü User; Nefise Öztoprak

Seroepidemiology and risk factors of hepatitis C virus infection in East Azerbaijan, Iran: a population-based Azar Cohort study.

PubMed 10(3) (2019)

Ali Asghar Pouri; Morteza Ghojazadeh; Behrouz Pourasghari; Babak Baiaz; Fatemeh Soghra Hamzavi; Mohammad Hossein Somi

Estado actual de la epidemiología, diagnóstico, tratamiento y control de la hepatitis C

Ciencia Tecnología y Salud 4(1) (2017)

Patricia Vélez-Möller

The Economic Burden of Viral hepatitis C infection at various stages of the disease in District Mardan, Pakistan

Pakistan BioMedical Journal (2022)

Sajjad Khan; Misbah Nosheen

Necessity to strengthen prevention activities and expand treatment services to accomplish global elimination of Hepatitis C

Annals of Tropical Medicine and Public Health 10(5) (2017)

Saurabh RamBihariLal Shrivastava; PrateekS Shrivastava; Jegadeesh Ramasamy

Ombitasvir/ Paritaprevir/ Ritonavir + Ribavirin Combination Therapy in Hepatitis C Virus Infected Patients with Genotype 4 in Real-life Practice: A Multicentre Experience

Infectious Diseases and Clinical Microbiology 1(2) (2019)

Bilgehan Aygen; Neşe Demirtürk; Orhan Yıldız; İ̇lhami Çelik; Deniz Kamalak Guzel; Gülden Ersöz; Ayşe Alga Batırel; Bahar Örmen; Faruk Karakeçili; Pınar Korkmaz; Nazan Tuna; Alper Şener; Rıza Aytaç Çeti̇nkaya; Emine Türkoğlu; Güliz Evik; Nesrin Türker; Umut Devrim Binay; Ercan Yeni̇lmez; Gökmen Zararsız

OpenAlex

Economic Burden of Hepatitis C Infection

Sofosbuvir based therapy in Hepatitis C patients with and without cirrhosis: Is there difference?

Hepatitis C virus-related policy-making in Iran: a stakeholder and social network analysis

Non-healthcare costs of hepatitis C: a systematic review

Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS)

Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review

Prevalence of HBV, HCV, and HIV Infections among Patients Undergoing Hemodialysis in Fasa, Iran: A Six-Year Follow-up Study

Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience